<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00221624</url>
  </required_header>
  <id_info>
    <org_study_id>7929-01</org_study_id>
    <secondary_id>2000-030</secondary_id>
    <nct_id>NCT00221624</nct_id>
  </id_info>
  <brief_title>Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients</brief_title>
  <acronym>PEGARI</acronym>
  <official_title>Randomized Placebo-Controlled Trial of a Triple Therapy Combining Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine Versus Peginterferon Alfa-2a Plus Ribavirin Plus Placebo in Hepatitis C-Infected Patients Non Responders to a First-Line Therapy of Interferon and Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Response to a second-line anti-HCV treatment in non responder patients to a first-line dual
      therapy remains very poor. Preliminary studies of amantadine suggest that this drug could be
      potentially effective to treat hepatitis C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background : Response to a second-line anti-HCV treatment in non responder patients to a
      first-line dual therapy remains very poor. Preliminary studies of amantadine suggest that
      this drug could be potentially effective to treat hepatitis C.

      Design : randomized, double-blind, multicenter trial.

      Interventions compared : Peg-interferon alfa 2A + ribavirin + amantadine versus
      Peg-interferon alfa 2A + ribavirin + Placebo

      Eligibility criteria : Chronic hepatitis C, previously treated with combination of interferon
      plus ribavirin for at least 24 weeks,detectable HCV RNA.

      primary outcome : sustained virological response, defined as an undetectable HCV RNA level 24
      weeks after the end of anti HCV treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sustained virological response, defined as an undetectable HCV RNA level 24 weeks after the end of anti HCV treatment (i.e. overall 72 weeks after randomization)</measure>
    <time_frame>24 weeks after the end of antiHCV treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALT &lt; upper limit of normal values,</measure>
    <time_frame>24 weeks after the end of anti-HCV treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>histological response according to METAVIR score</measure>
    <time_frame>24 weeks after the end of anti-HCV treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life assessed</measure>
    <time_frame>at week 72</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">131</enrollment>
  <condition>HCV Infection</condition>
  <condition>Hepatitis C, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amantadine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis C

          -  Previously treated with a combination of interferon plus ribavirin for at least 24
             weeks

          -  Detectable HCV RNA (i.e. non responders)

          -  Signed informed consent

        Exclusion Criteria:

          -  Evidence of another cause of liver disease

          -  Liver cirrhosis (child-Pugh stage BMC)

          -  Alcohol consumption &gt; 30g/day for women or &gt; 40g/day for men ; drug abuse

          -  Other serious relevant disorders : psychiatric condition (especially depression),
             cardio-vascular disease, renal decompensation, seizure history, hemoglobinopathy,
             auto-immune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice Couzigou, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geneviève Chêne, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d’hépato-Gastro-Entérologie - Hôpital Haut Leveque - avenue de Magellan</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>June 12, 2007</last_update_submitted>
  <last_update_submitted_qc>June 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2007</last_update_posted>
  <keyword>Hepatitis C, chronic</keyword>
  <keyword>HCV infection</keyword>
  <keyword>Treatment failure</keyword>
  <keyword>PEG Interferon</keyword>
  <keyword>(Interferons/therapeutic use</keyword>
  <keyword>Interferon Alfa-2a/adverse effects)</keyword>
  <keyword>ribavirin</keyword>
  <keyword>(Ribavirin/therapeutic use</keyword>
  <keyword>Ribavirin/adverse effects)</keyword>
  <keyword>Amantadine</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

